( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive (HPV16+) head and neck cancers. The data were published in the Company's abstract for the ASCO 2024 Annual Meeting and support the Company's pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab in the first line setting.
The abstract reported data as of January 12, 2024, and included 42 patients treated with HB-200 plus pembrolizumab. The treatment was generally well tolerated with a low rate of treatment -related discontinuation and no treatment -related deaths. Among a subpopulation of 17 evaluable patients with CPS of 20 or higher, the updated data showed confirmed ORR of 53 percent, CR rate of 18 percent, and DCR of 82 percent.
This subpopulation is representative of patients eligible for the Company's pivotal Phase 2/3 trial, which will begin enrolling patients in the fourth quarter of 2024. Additional data will be presented in the Head and Neck Oral Abstract Session at the ASCO 2024 Annual Meeting on June 4, at 11:09 a.m.
CDT. During the presentation, preliminary progression-free survival and overall survival data will be shared for the first time. “We are happy to provide an .
